Mednet Logo
HomeDermatology
Dermatology

Dermatology

Clinical insights on skin conditions, dermatologic procedures, and treatment approaches from practicing dermatologists.

Recent Discussions

How would you approach management of a large, fungating squamous cell carcinoma of the auricle if surgical management is not desired by the patient?

3
4 Answers

Mednet Member
Mednet Member
Radiation Oncology · West Virginia University

For a tumor this size and with cartilage invasion, I would recommend starting with induction cemiplimab to best response (generally 4-6 cycles), followed by consolidative RT, generally electrons. Prior to starting the immunotherapy, I would stage the neck with a contrast CT scan, as tumors of this s...

How do you approach patients who continue to experience pruritus and ongoing concern for persistent scabies despite having completed appropriate treatment?

1
7 Answers

Mednet Member
Mednet Member
Dermatology · Duke Health

Pruritus can not uncommonly continue in patients for 6 weeks or more after infestation is managed. High-dose antihistamines may be of some benefit. Consider if there is an ongoing untreated exposure that the patient has not thought of or cannot/will not share with you. Not all people infested with s...

How do you counsel patients with pemhigus on the main safety benefits of a low or ultra low dose rituximab regimen?

2 Answers

Mednet Member
Mednet Member
Dermatology · Duke University

Although I read this article with interest and an open mind, I have not adopted ultra-low dose rituximab into my clinical practice of treating pemphigus patients for several reasons. The author's conclusions may very well end up being correct over time, but there are too many concerns with the study...

Would you continue cemiplimab adjuvantly, following resection of initially unresectable cutaneous squamous cell carcinoma treated with downstaging immunotherapy?

5 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Texas MD Anderson Cancer Center

This is a challenging question because, as you know, we have no randomized data to address it. I generally do not continue immune checkpoint therapy after resection of SCC skin. However, given the adjuvant data in melanoma and the high efficacy of anti-PD1 in skin SCC, I do think it is reasonable to...

What are your favorite modalities for preventing hypergranulation tissue?

1 Answers

Mednet Member
Mednet Member
Dermatology · University of California Irvine

Although exuberant granulation tissue is not totally preventable nor predictable, persistent inflammatory impetus, such as from hairs embedded in a surgical closure, or spitting suture reactions, can stimulate excess granulation tissue. Careful avoidance of trapped hairs as well as burying absorbabl...

How do you treat gram-negative folliculitis in a transplant patient on sirolimus who cannot use isotretinoin due to drug interactions?

1
2 Answers

Mednet Member
Mednet Member
Dermatology · Thomas Jefferson University Hospital

The most critical issue with these infections in the immunocompromised host is the correct identification of the organism and its sensitivities to allow appropriate selection and course of antibiotics. Because the infection is deep in the hair follicle and the patient will shave the area, there is a...

Is keratosis follicularis (Darier disease) a contraindication to the receipt of PMRT?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Mayo Clinic Hospital

Thanks for this interesting question. It prompted me to do a bit of literature search and think about how I'd approach this case.For a postmenopausal patient with ER-negative, PR-negative, HER2-negative (triple-negative) pT2N0(sn) breast cancer and unresectable positive surgical margins after mastec...

How have you applied the findings of this trial to your current approach to prescribing rituximab for pemphigus patients?

3 Answers

Mednet Member
Mednet Member
Dermatology · University of Pennsylvania

For the MMF vs MMF + Rituximab trial, the patients received two courses of Rituximab six months apart. The B cells don’t start to recover until about six months after the infusions. The data shows more patients in the rituximab group achieved sustained CRoff pred for 15 weeks or more relative to MMF...

Would you stop bimekizumab in a patient who has severe psoriasis and has responded well to this therapy but is found to have newly diagnosed cirrhosis?

1 Answers

Mednet Member
Mednet Member
Dermatology · Wake Forest University

I'd want to know if there was some other cause for the cirrhosis. If there were, I would not stop the bimekizumab. If there was not a clear, obvious cause, I'd want the patient evaluated by a hepatologist. If the hepatologist could find some other reason for the cirrhosis, it might not be necessary ...

How do you manage recurrent scabies in both a patient and their partner when standard therapy fails?

1 Answers

Mednet Member
Mednet Member
Dermatology · University Hospitals

I would recommend 2 weekly treatments with oral ivermectin and topical permethrin. It is also very important to discuss control of fomite exposure as well as possible occult sources e.g., relatives and close friends.